Laser Beam Therapeutics

Company Overview

Snapshot

Founded in July 2016 by Alon Sinai and Miri Sani, Laser Beam Therapeutics operates with 1–10 employees. The company has raised $330,000 across one funding round from one investor. In January 2020, the company secured its seed funding.

Business overview

Laser Beam Therapeutics (LBT) develops a treatment solution designed to improve the prognosis for acute myocardial infarction (MI) patients. The company's core technology involves external laser activation to mobilize stem cells into the circulatory system, which then target and work to reverse scarring from MI. LBT's CardioZ16 Laser Device stimulates bone marrow to accelerate tissue repair. The company operates within the Health Tech & Life Sciences sector, with applications also showing promise in gastroenterology and neurological conditions such as Alzheimer's disease.

Company Intelligence Q&A

What is the primary focus of Laser Beam Therapeutics?

Laser Beam Therapeutics focuses on developing laser therapy solutions to improve the prognosis in cases of acute myocardial infarction (MI) by mobilizing stem cells to reverse scarring.

Who founded Laser Beam Therapeutics?

Laser Beam Therapeutics was co-founded by Alon Sinai, who serves as CEO, and Miri Sani, who is the VP Regulatory Affairs.

What is the CardioZ16 Laser Device?

The CardioZ16 Laser Device is a product by Laser Beam Therapeutics that uses light to stimulate bone marrow, speeding up tissue repair in various parts of the body.

When was Laser Beam Therapeutics founded?

Laser Beam Therapeutics was founded in July 2016.

What is the current status of Laser Beam Therapeutics?

Laser Beam Therapeutics is currently non-active, having ceased operations in January 2024.